Track Johnson & Johnson's total liabilities ($-85B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2026), JNJ shows a total liabilities of $-85B. That compares with $110B in the prior-year period — down 174.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, JNJ's total liabilities is now $-85B (was $110B) — a 174.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Johnson & Johnson is outperforming or lagging.
Tracking JNJ's total liabilities over time shows whether Johnson & Johnson is scaling, shrinking, or reshaping that part of the business. The current reading is $-85B That compares with $110B in the prior-year period — down 174.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has Johnson & Johnson's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $-85B) with ownership activity and broader fundamentals.
Johnson & Johnson's total liabilities is $-85B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.